Science for cure
Personalised cancer therapy
Providing hope for cancer patients: Our vision for a better future
Imagine a world where cancer patients who lack effective treatment options can be cured. With our innovative cell therapy product, currently in clinical trial, we are bringing this vision closer to reality. Our unique approach trains the patient’s own immune cells to target and eliminate cancer cells, providing a tailor-made treatment for each patient.
The story of Neogap
Neogap Therapeutics is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology.
Discover Neogap's innovative pTTL cell therapy and patented technology
Our pTTL cell therapy product, which targets neoantigens, is just one example of our novel technology at Neogap. Manufactured using our proprietary PIOR® and patented EpiTCer® technologies, pTTL consists of T cells targeting neoantigens using immune cells from cancer patients as starting material.
The growing colorectal cancer therapeutics market
Neogap is dedicated to advancing the field of personalised immunotherapy to combat cancer, starting with our focus on colorectal cancer. Our experienced team of professionals from academia and the pharmaceutical industry is committed to developing innovative solutions that are at the forefront of cancer research. Our pTTL cell therapy product is a testament to this dedication.
We also believe in the power of collaboration and are open to partnering with organisations that share our vision for advancing the field of personalised immunotherapy for cancer treatment.
Latest news from Neogap
Neogap selected by EIC for BIO International Convention 2026
Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has been selected by the European Innovation Council (EIC) to join its delegation at BIO International Convention 2026 – the world’s largest partnering event in biotechnology. As one of a limited number of selected European life science companies, Neogap will participate in the EIC Pavilion to engage with potential global partners and advance business development discussions.
Neogap secures SEK 87 million to advance clinical development of its personalised immunotherapy
Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has raised SEK 87 million in a financing round led by Sciety. The capital will be used to advance the company’s ongoing clinical study and to build the data required for the next stage of Neogap’s development programme.
Neogap featured in Expressen
In connection with World Cancer Day on 4 February, Expressen published an article focusing on ongoing cancer research and clinical development in Sweden, including work within personalised cancer immunotherapy. The article discusses current challenges in colorectal cancer and the importance of long-term, clinically grounded development of more individualised treatment approaches.